Announcement

Collapse
No announcement yet.

J Infect Dis. Cross-reactive and vaccine-induced antibody to emerging swine influenza A(H3N2)v

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • J Infect Dis. Cross-reactive and vaccine-induced antibody to emerging swine influenza A(H3N2)v

    [Source: Journal of Infectious Diseases, full text: (LINK). Abstract, edited.]
    Cross-reactive and vaccine-induced antibody to emerging swine influenza A(H3N2)v


    Danuta M. Skowronski*,1,2, Naveed Z. Janjua 1,2, Gaston De Serres 3,4,5, Dale Purych 2,6, Vladimir Gilca 3,4,5, David W. Scheifele 2,7, Marc Dionne 3,4,5, Suzana Sabaiduc 1, Jennifer L. Gardy 1,2, Guiyun Li 1, Nathalie Bastien 8, Martin Petric 1,2, Guy Boivin 4,5 and Yan Li 8

    Author Affiliations: <SUP>1</SUP>British Columbia Centre for Disease Control, Vancouver, Canada <SUP>2</SUP>University of British Columbia, Vancouver, Canada <SUP>3</SUP>Institut National de Sant? Publique du Qu?bec [National Institute of Health of Quebec], Qu?bec, Canada <SUP>4</SUP>Laval University, Quebec, Canada <SUP>5</SUP>Centre Hospitalier Universitaire de Qu?bec [University Hospital Centre of Quebec], Qu?bec, Canada <SUP>6</SUP>BC Biomedical Laboratories Ltd, Surrey, Canada <SUP>7</SUP>Vaccine Evaluation Centre, Child and Family Research Institute, Vancouver, Canada <SUP>8</SUP>National Microbiology Laboratory, Winnipeg, Manitoba, Canada

    *Corresponding author: Danuta M. Skowronski, 655 West 12<SUP>th</SUP> Avenue, Vancouver, British Columbia, Canada V5Z 4R4; ph: 604-707-2511; fax 604-707-2516; Email: danuta.skowronski@bccdc.ca

    Alternate corresponding author: Naveed Z. Janjua, 655 West 12<SUP>th</SUP> Avenue, Vancouver, British Columbia, Canada V5Z 4R4; ph: 604-707-2514; fax 604-707-2516; Email: naveed.janjua@bccdc.ca



    Abstract

    Background.

    Cases of a novel swine-origin influenza A(H3N2) variant (A(H3N2)v) have recently been identified in the US, primarily among children. We estimate cross-reactive antibody to A(H3N2)v by age and assess whether seasonal trivalent inactivated influenza vaccine(TIV),with/without adjuvant, may improve sero-protection.


    Methods.

    Antibody to A(H3N2)v was assessed by hemagglutination inhibition(HI) and a subset also by microneutralization. Sero-prevalence/sero-protection were defined at HI titre≥40 and compared against ancestral and contemporary human strains. Analysis included 1116 sera collected during fall,2010 as ~100 sera/decade of life. Vaccine-induced antibody was assessed in pre-/post-immunization sera collected from 136 children <10years and 65 adults 20-59years given 2010-11 split TIV, and from 182 elderly ≥65years given 2011-12 split(n=31), MF59-adjuvanted(n=72), or unadjuvanted subunit TIV(n=79).


    Results.

    Overall prevalence with HI titre≥40 against A(H3N2)v was 25%. None<5years, and <20% up to 14years or over 40years had titre≥40. Conversely, between 14 and 40years, half of teens and adults showed A(H3N2)v sero-protection. Following TIV receipt, <15% in any vaccine group developed 4-fold antibody rise.


    Conclusions.

    A substantial proportion of adolescents and young adults have cross-reactive antibody against A(H3N2)v, whereas children and older adults show broad susceptibility. Recent formulations of TIV do not substantially improve sero-protection. A specific vaccine would be needed in the event A(H3N2)v establishes epidemic spread.



    Footnotes
    • Received April 23, 2012.
    • Revision received July 17, 2012.
    • Accepted July 23, 2012.
    • ? The Author 2012. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com
    -
    ------
Working...
X